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Streptococcus pneumoniae remains a leading cause of morbidity and mortality world-
wide.The highly adaptive nature of S. pneumoniae exempliﬁes the need for next generation
antimicrobials designed to avoid high level resistance. Metal based nanomaterials ﬁt this
criterion. Our study examined the antimicrobial activity of gold nanospheres, silver coated
polyvinyl pyrrolidone (AgPVP), and titanium dioxide (TiO2) against various serotypes of S.
pneumoniae. Twenty nanometer spherical AgPVP demonstrated the highest level of killing
among the tested materials. AgPVP (0.6 mg/mL) was able to kill pneumococcal serotypes
2, 3, 4, and 19F within 4 h of exposure. Detailed analysis of cultures during exposure
to AgPVP showed that both the metal ions and the solid nanoparticles participate in the
killing of the pneumococcus.The bactericidal effect of AgPVP was lessened in the absence
of the pneumococcal capsular polysaccharide. Capsule negative strains, JD908 and RX1,
were only susceptible to AgPVP at concentrations at least 33% higher than their respective
capsule expressing counterparts.These ﬁndings suggest thatmechanismsof killing used by
nanomaterials are not serotype dependent and that the capsular polysaccharide participates
in the inhibition. In the near future these mechanisms will be examined as targets for novel
antimicrobials.
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INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is an encapsulated,
Gram-positive, facultative anaerobic bacterium which is a com-
mon commensal in the nasopharynxof healthy adults and children
(Zemlickova et al., 2006; Calix et al., 2012; Marks et al., 2013).
Asymptomatic carriage of S. pneumoniae can lead to invasive
and non-invasive infections (Morona et al., 2004; Abdelnour et al.,
2009; Ghasemi et al., 2009). Symptomatic disease will occur when
the bacteriummigrates to normally sterile organs such as the lungs,
spinal cord, and middle ear (Murkerji et al., 2012). Such infec-
tions have been associated with high morbidity and mortality in
young children under 5 years of age, the elderly, and immuno-
compromised especially in developing countries (Ghasemi et al.,
2009; Mehr and Wood, 2012). Annually, in the United States,
there are an estimated 500,000 cases of pneumonia, 50,000
cases of bacteremia, 3,000–6,000 cases of meningitis, 7,000,000
cases of otitis media with the major cause being pneumococ-
cus (Temime et al., 2008; Daka et al., 2011; CDC, 2013). It has
also been estimated by the World Health Organization that 2
million children, under the age of ﬁve, die each year from com-
plications associated with pneumococcal pneumonia including
endobronchial obstruction, empyema, and pericarditis (Bryce
et al., 2005).
The highly recombinant nature of S. pneumoniae in combina-
tion with naturally occurring antibiotic resistance and the overuse
of antibiotics are all likely to contribute to the organism’s increas-
ing levels of antibiotic insensitivity. While β-lactams remain the
preferred treatment for pneumococcal infection, their usefulness is
limited due to increasing resistance to several classes of antimicro-
bials. The morbidity and mortality associated with pneumococcal
infections, as well as the ever declining level of antibiotic suscepti-
bility and limited usefulness of prophylaxis, point to the need for
novel antimicrobials.
Nanomaterials have shown some usefulness in killing
pathogenic bacteria. Some nanoparticles (NPs), typically on the
0.2–100 nm scale, (El-Nour et al., 2010; Beer et al., 2012; Sun
et al., 2013) are ﬁnding increasing application as antimicrobials
and additives in food packaging, industrial and consumer prod-
ucts (Ravishankar and Jamuna, 2011; Sahayaraj and Rajesh, 2011;
Ivask et al., 2012). Metal NPs have been of great interest due to
their physiochemical properties (e.g., electromagnetic, optic and
molecular recognition, and catalytic) that differ from bulk materi-
als of micro-size (Kaittanis et al., 2010; Sadeghi et al., 2010; Ahmad
et al., 2013). Higher activity of nanoscale materials is a result of
their surface-to-volume ratios. As the material becomes smaller,
the percentage of active molecules/atoms present at the surface
increases compared to larger bulk material.
The advantages of using metallic NPs are as follows: (1) core of
the material is inert, (2) exploitation of both chemical and physical
properties enables them to carry and release various therapeutic
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agents, (3) synthesis is relatively simple and (4) mechanism of
action allows versatility. Once the metal is ionized, it becomes very
reactive as it interacts with thiol group of respiratory enzymes
that are located in the bacterial cell wall or cell membrane (Ghosh
et al., 2008). When the NPs enter the cell, they will migrate to
the center of the bacteria. The bacteria conglomerate in an effort
to protect its DNA from the metal ions. This event will eventu-
ally cause the DNA to condense leading to the retardation of the
respiratory chain, cell division, and ﬁnally cell death (Rai et al.,
2009; Sadeghi et al., 2010; Arshi et al., 2011). Microbes would
need to acquire a range of mutations to gain resistance against the
metals effects. This makes NPs good candidates as antimicrobial
agents.
The goals of the current study were to examine the antimi-
crobial effect of metallic NPs against clinically relevant serotypes
of S. pneumoniae and to determine if the capsular polysaccharide
plays a role in the inhibition. Each of these ﬁndings is novel to
S. pneumoniae research.
MATERIALS AND METHODS
NANOPARTICLE AND SYNTHESIS
Silver polyvinyl pyrrolidone (AgPVP) coated NPs (20 nm) and
titanium dioxide (Anatase; 15 nm) were purchased from Nanos-
tructured and Amorphous Materials, Inc. (Houston, TX, USA).
Gold nanospheres were synthesized from hydrogen tetrachloroau-
rate (III), HAuCl4, (Sigma Aldrich; Kimling et al., 2006). Gold
hydrochlorate (HAuCl4) was dissolved in deionized water and
heated to 100◦C with vigorous stirring. Heated sodium citrate
was added and allowed to stir for 30 min. The color of the
solution gradually changed from faint yellow to gray then deep
purple before becoming wine red. The process produced spher-
ical 20 nm particles. All NPs were examined using transmission
electron microscopy (TEM).
BACTERIA STRAINS AND CULTURING
RX1 (Morona et al., 2004; Marks et al., 2012; Murkerji et al., 2012)
was a gift from David E. Briles at the University of Alabama at
Birmingham, Birmingham,AL,USA. The capsular polysaccharide
deﬁcient S. pneumoniae strain JD908 (Magee and Yother, 2001;
Marks et al., 2012) was provided by Janet Yother at the Univer-
sity of Alabama at Birmingham, Birmingham Alabama. JD908
was grown in the presence of erythromycin (0.3 μg/mL). All S.
pneumoniae strains used in the study are listed in Table 1. Strains
were grown in Todd Hewitt broth supplemented with 0.5% yeast
extract (THY). Bacteria were quantitated and stored at −80◦C
until use.
DETERMINATION OF ANTIMICROBIAL ACTIVITY IN LIQUID CULTURE
In a variation of the microdilution technique, S. pneumoniae cul-
tureswere diluted to 1.0× 103 CFU/mL inTHYand grown in 4mL
cultures in the presence of various concentrations of metallic NPs
at 37◦C for 5 h to determine the minimum bactericidal concen-
tration (MBC) of the NPs (Gnanadhas et al., 2013; Yadav et al.,
2013). The 5 h incubation was chosen because our preliminary
data showed that in cultures where complete killing was seen, cell
death occurred prior to the 5 h time point. Following incubation,
serial dilutions of the bacteria were plated on tryptic soy agar sup-
plemented with 5% sheep blood. Following overnight incubation
at 37◦C, the bacteria were quantitated.
QUANTITATION OF METAL ION RELEASE FROM NANOPARTICLES
Titanium dioxide (95 mg/mL), AgPVP (0.6 mg/mL), and activity
of gold nanospheres (AuNP; 1 mg/mL) were incubated individu-
ally in THY media for 5 h at 37◦C.Ag andAu ions released into the
mediaweremeasuredusing laser inducedbreakdown spectroscopy
(LIBS). The measurement settings were a modiﬁcation of Barnett
et al. (2011). The excitation wavelength used was 266 nm and the
laser energy was adjusted to 20 mJ. The spectrometer and detector
were changed to the Andor Shamrock 303i – iStar – DH320T-25F-
03 with gating at 2400 l/mm. Data was collected approximately
1.5 μs after the plasma started and the signal was integrated for
3.0 μs. Gold was monitored using Au I at 267.60 nm and while
silver was monitored using Ag I at 328.07 and 338.29 nm.
Ti was measured using a standard curve and measuring the
optical density at 360 nm.
CHARACTERIZATION OF S. pneumoniae/AgPVP INTERACTIONS
Streptococcus pneumoniae D39 (1.0 × 103 CFU/mL) was grown in
THY in the presence of AgPVP (0.6 mg/mL) NPs and incubated
at 37◦C for 5 h. At various time points, cultures were pelleted
by centrifugation for 15 min at 2012 × g. After centrifugation,
the supernatant was removed and the pellet was washed using
phosphate buffer saline (1XPBS) then pelleted. Bacteria were ﬁxed
using 2.5% Glutaraldehyde, 1% osmium tetroxide, and 1XPBS.
Images were captured via Scanning electron microscopy (ZEISS
EVO 50VP).
Table 1 | Streptococcus pneumoniae strains included in the study.
Name Serotype Background
strain
Penicillin Erythromycin Reference
D39 2 NA Sensitive Sensitive Magee andYother (2001), Sanders et al. (2011), Murkerji et al. (2012)
WU2 3 NA Sensitive Sensitive Magee andYother (2001), Li et al. (2009), Ren et al. (2012)
TIGR4 4 NA Sensitive Sensitive Weinberger et al. (2009), Melin et al. (2010), Murkerji et al. (2012)
EF3030 19F NA Sensitive Sensitive Johnston et al. (2006), Coats et al. (2011)
RX1 2 D39 Sensitive Sensitive Morona et al. (2004), Marks et al. (2012), Murkerji et al. (2012)
JD908 3 WU2 Sensitive R (0.03 μg/mL) Magee andYother (2001), Marks et al. (2012)
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STATISTICS
Differences between S. pneumoniae (WT) strains were compared
with their capsular negative mutants using a two sample, inde-
pendent Student t-test. A P value of <0.05 was considered
signiﬁcant.
RESULTS
ANALYSIS OF NANOMATERIALS
Transmission electron microscopy showed the AuNP, AgPVP, and
TiO2 to be 20 nm, 20 nm, and 15 nm respectively, with uniform
particle distribution (Figure 1A). All particles were spherical. The
FT-IR spectra for each NP correlate with the ﬁngerprint expected
for the respective particle (Figure 1B) (Huang et al., 2010; Tiwari
et al., 2011; Devika et al., 2012).
MINIMUM BACTERICIDAL CONCENTRATIONS
Streptococcus pneumoniae strain D39 was grown in liquid media
in the presence of varying concentrations of AuNP, AgPVP, or
TiO2. The minimum concentrations of TiO2 and AgPVP needed
to kill S. pneumoniae D39 were determined to be 95 mg/mL and
0.6 mg/mL respectively, (Figure 2). AuNP at concentrations up
to 0.8 mg/mL were able to cause a maximum decrease of 9% in
the culture’s viability. Higher concentrations of AuNP were not
examined because the bactericidal effect plateaued at concentra-
tions above 0.4 mg/mL (Figure 2). When AgPVP and TiO2 were
examined for their ability to kill various S. pneumoniae strains of
varying serotypes, AgPVP gave more consistent effects than TiO2
(data not shown). All tests were done in duplicate and repeated
twice. The bactericidal action of metallic NPs is largely attributed
to the release of metal ions from the particle. The levels of Ag, Au,
and Ti in the culture media at the end of the 5 h incubation period
were determined to be<2.5 μg/mL, 0.0078 μg/mL and 20 mg/mL
respectively.
NON-SEROTYPE DEPENDENT ANTIBACTERIAL ACTIVITY OF AgPVP
The 93 serotypes of S. pneumoniae are not equal in their ability
to cause disease or their behavior in vitro. In order to determine
the effect of serotype on the antimicrobial effect of metallic nano-
materials, four pathogenic S. pneumoniae serotypes were tested for
the ability to survive in the previously determined MBC of AgPVP.
S. pneumoniae isolatesD39 (serotype 2),WU2 (serotype 3), TIGR4
(serotype 4), and EF3030 (serotype 19F) were grown in the pres-
ence of AgPVP (0.6 mg/mL; Figure 3). While all the tested isolates
were susceptible to AgPVP at the test concentration, the time
required to completely kill the cultures varied. Also, while the time
to death varied between the individual strains none survived more
than 4 h. Due to the variation in survival times for the individ-
ual strains representing the various serotypes, additional strains
within the serogroups were tested for survival in the presence of
0.6 mg/mL AgPVP. The length of time individual strains survived
varied among strains of the same serotype (data not shown). These
ﬁndings together suggest that inhibition is not dependent on the
serotype.
CAPSULAR POLYSACCHARIDE INFLUENCED KILLING OF S. pneumoniae
The variability in time to death during exposure to AgPVP for
the individual serotypes suggests that the capsular polysaccha-
ride may play a role in the interaction between bacteria and NPs.
FIGURE 1 | Characterization of nanoparticles. (A)TEM Images of AuNP, AgPVP, andTiO2 nanoparticles. Nanomaterials were deposited onto a copper grid for
imaging. (B) FT-IR spectra of nanoparticles. Most relevant peaks are circled.
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FIGURE 2 | Metallic nanoparticles have varying effects on
pneumococcal growth. Pneumococcal strain D39 was grown in liquid
media in the presence of (A) gold nanospheres (AuNP), (B) titanium dioxide
(TiO2), and (C) silver coated polyvinyl pyrrolidone (AgPVP). Bars represent
the Log10 of the mean number of surviving organisms following a 5 h
growth period. Errors are the SD of grouped data.
In order to examine the effect of the pneumococcal capsule on
the antimicrobial activity of metallic NPs, S. pneumoniae D39,
WU2 and their capsular polysaccharide negative mutants, Rx1 and
JD908, respectively, were grown for 5 h in the presence of AgPVP
(Figure 4). Rx1 and JD908 were found to survive signiﬁcantly
longer and in higher numbers than their respective wild-type
counterparts (P = 0.0005 and P = 0.003, respectively). In fact, the
mutant strains lacking capsular polysaccharide remained viable
in the presence of AgPVP. RX1 maintained the number of viable
colonies while JD908 increased in CFU. Increasing the incuba-
tion time did not result in death of the mutant strains due to
AgPVP (data not shown). AgPVP concentrations of 0.8 mg/mL
and higher were able to kill RX1 and JD908 S. pneumoniae. The
growth patterns and responses to AgPVP suggest that the capsular
polysaccharide participates in the mechanism used by AgPVP to
kill S. pneumoniae.
ULTRASTRUCTURAL EFFECT OF AgPVP
Scanning electron microscopy of S. pneumoniae D39 grown in the
presence of AgPVP demonstrated the killing of the bacterial cells
in the presence of the nanomaterial (Figures 5D–F). AgPVP alone
is shown in Figure 5B. Images were taken at 0 h (Figure 5A) and
5 h incubation (Figures 5C–F). The cell debris remaining follow-
ing exposure of the bacteria to AgPVP is shown in Figure 5D.
Figure 5C shows bacteria grown in the absence of AgPVP. The
absence of cell debris in the Figure 5C sample indicates that the
debris seen in Figure 5D is not attributable to autolysis of the
bacteria. The damage and breakdown of the bacterial capsular
polysaccharide and cell wall can be seen in Figure 5E and is indi-
cated by the arrow. Also, while much of the damage done by
metallic NPs is thought to be due to the metal ions, the NPs them-
selves do participate in the inhibition of the bacteria as is seen in
Figure 5F which shows AgPVP inside the bacteria (indicated by
arrow). As the particles accumulate in the bacteria the bacteria
increase in size and eventually lyse.
DISCUSSION
For decades, metal ions and metal based compounds have been
used in various capacities due to their antimicrobial properties
against different pathogenic microorganisms (Zhou et al., 2012;
Ahmad et al., 2013; Lima et al., 2013). The present study is the ﬁrst
detailed examination of the potential use of metallic NPs against
clinically relevant serotypes of the formidable human pathogen,
S. pneumoniae. Due to their varying modes of action, Au, Ag,
and TiO2 NPs were examined for antimicrobial effects against
S. pneumoniae. AgNP showed the most reproducible inhibition.
This is likely due to multifaceted damage caused AgNPs includ-
ing condensation of DNA, cell membrane separation from the
cell wall, and cell wall damage (Morones et al., 2005; Seil and
Webster, 2012; You et al., 2012). The levels of AgNPs needed to
inhibit pneumococcal growth are higher than those reported for
other microorganisms (Pelgrift and Friedman, 2013; Losasso et al.,
2014). This is likely due to the unique physical characteristics of the
bacterium. The lack of inhibition by AuNPs is likely because their
antimicrobial effect is due to the targeting of sulfur-containing
proteins present in the membrane or inside the cells but S. pneu-
moniae does not contain many such proteins. Also, a much smaller
percentage of Au ions were released into the media. TiO2 is more
limited in its activity due to the need for activation by UV light or
the availability of doped catalysts (Kuhn et al., 2003; Pelgrift and
Friedman, 2013).
The role of the capsular polysaccharide in protecting the pneu-
mococcus is well documented (Magee and Yother, 2001; Melin
et al., 2010; Sanders et al., 2011). The capsular is also a major con-
tributor for the organism’s pathogenicity and is the basis for the 93
known antigenically distinct serotype classiﬁcations (Hyams et al.,
2010; Hathaway et al., 2012; Wyres et al., 2012). Disease serotypes
2, 3, 4, and 19F were all found to be susceptible to the antimi-
crobial effects of AgPVP. These serotypes are particularly relevant
because isolates of each serotype have been shown to be virulent
in animal models of infection as well as human disease (Coats
et al., 2011; Hotomi et al., 2013; Okade et al., 2014). This ﬁnding
supports the likelihood that other disease causing serotypes will be
susceptible as well. Having broad range applicability to pneumo-
coccal infection makes NPs far more attractive in the war against
pneumococcal infection.
During infection, the capsule protects S. pneumoniae from
opsonophagocytosis. This protective role of the capsule can appear
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FIGURE 3 | Streptococcus pneumoniae strains of different serogroups
respond differently in the presence of Ag-PVP. Strains (A) D39 (serotype 2),
(B)WU2 (serotype 3), (C)TIGR4 (serotype 4), and (D) EF3030 (serotype 19F)
were grown in the presence of Ag-PVP (0.6 mg/mL). Samples were tested in
duplicate and repeated twice. Symbols represent the average viable CFU
(Log10) and the SD of grouped data.
FIGURE 4 | Capsular polysaccharide contributes to S. pneumoniae’s
sensitivity to AgPVP. (A) D39, serotype 2 and (B)WU2, serotype 3, along
with their capsule polysaccharide negative mutants were grown in the
presence of 0.6 mg/mL AgPVP nanoparticles for 5 h. Rx1 survived in
signiﬁcantly higher numbers than D39 (P = 0.0005) as did JD908 when
compared toWU2 (P = 0.003).
counterintuitive when considered alongside our data showing that
S. pneumoniae strains completely lacking a capsular polysaccha-
ride were less susceptible to the effects of metallic nanomaterials.
In reality, this ﬁnding suggests a yet undeﬁned role of the cap-
sule in the presence of metallic ions and possible nanomaterials
in general. One possible mechanism is the capsule aiding in the
accumulation of metal ions near the cell wall where they can more
easily access the cell membrane. A second possibility involves the
capsule participating in the movement of metal ions or whole NPs
into the bacterial cells.
Additionally, while the capsule polysaccharide appears to par-
ticipate in killing of the pneumococcus by nanomaterials this
does not undermine the use of these nanomaterials in the pos-
sible treatment of pneumococcal disease. This is because the
capsule polysaccharide is essential for infection by the pneu-
mococcus (Hammerschmidt et al., 2005; Weinberger et al., 2009;
Hyams et al., 2010). Thus if the bacteria respond to the presence
of an antimicrobial by decreasing its’ capsular polysaccharide, the
bacteria would be rapidly cleared by the immune system.
Following exposure to AgPVP, there was a decrease in the
viable number of S. pneumoniae. This strongly suggests that
the bacteria were killed by the NP. Cell death is further sup-
ported by the cell lysis that was visible when the culture was
examined using microscopy. The breakdown of the cell capsu-
lar polysaccharide and cell wall are irreversible and conclusively
shows that the organism was not in a viable but non-cultureable
state.
The behavior of organisms S. pneumoniae in the presence of
various nanomaterials provides valuable insight into the possibil-
ity of novel antimicrobials to treat pneumococcal diseases. While
AgPVP is not likely to be used to treat S. pneumoniae infection
due to its documented toxicity of Ag and AgNPs (Ahamed et al.,
2010; Asharani et al., 2011; Hamilton et al., 2014) the identiﬁed
vulnerability of different pathways used by AgPVP to inhibit
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FIGURE 5 | Silver coated polyvinyl pyrrolidone has a lytic effect on
S. pneumoniae. Scanning electron microscopy images of S. pneumoniae
grown in the presence and absence of AgPVP. S. pneumoniae D39 was expo-
sed to AgPVP for 0 (A) and 5 h (C–F). Cultures exposed to AgPVP were
compared to unexposed samples (C). AgPVP particles alone imaged as well (B).
Samples were deposited onto a glass slide mounted on a stud for imaging.
growth can give new areas on which to focus design of new
drugs.
CONCLUSION
The results obtained show spherical AgPVP to be preferential to
AuNP and TiO2 for the killing of S. pneumoniae. The inhibi-
tion occurred within 4 h of exposure to the nanomaterial, was
bactericidal in nature and involves the presence of the capsular
polysaccharide.
The susceptibility of several disease relevant pneumococcal
serotypes to inhibition by AgPVP is particularly encouraging due
to the variability of microorganism. The precise role of the cap-
sular polysaccharide in the killing of S. pneumoniae needs to
be examined. This will require the examination of organisms
expressing various levels of the capsule as well as organisms whose
serotype has not been identiﬁed.
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